Back to today’s briefing

Story perspectives

Breakthrough Hair Loss Treatment Shows 539% Improvement in Trials

12/4/2025

38 3 Full Breakdown

Summary

Story summary

Cosmo Pharmaceuticals announced two Phase III trials of clascoterone for male pattern baldness (AGA) involving nearly 1,500 men, showing significant hair restoration and that the treatment is not systemically absorbed.
A trial reported a 539% improvement over placebo.
If approved, it would be the first new AGA treatment in 30 years.
Cosmo plans to file for U.S. and EU approval after follow-up safety study by spring 2026.

1 of 1

Story summary

Cosmo Pharmaceuticals announced two Phase III trials of clascoterone for male pattern baldness (AGA) involving nearly 1,500 men, showing significant hair restoration and that the treatment is not systemically absorbed.
A trial reported a 539% improvement over placebo.
If approved, it would be the first new AGA treatment in 30 years.
Cosmo plans to file for U.S. and EU approval after follow-up safety study by spring 2026.